Practice

Editorial Argues That Nocebo Effect Could Harm Patients Who Switch to Biosimilars

February 27th 2018

By Samantha DiGrande

A recently published editorial linked to a previous switching study for patients who had been receiving reference infliximab (Remicade) to biosimilar infliximab (Inflectra) argues that the positive results of the trial “apparently settles the case in favor of unrestricted switching of 'expensive' originator to 'cheap' biosimilar infliximab. Yet, the devil is the details."

The Top 5 Biosimilars Articles for the Week of February 19

February 23rd 2018

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 19, 2018.

Anti-Infliximab Antibodies Can Guide Treatment Intensification in Patients With CD

February 23rd 2018

By Samantha DiGrande

A study published in Alimentary Pharmacology Therapeutics in December 2017 compared the outcomes, pharmacokinetics, and immunogenicity of treatment intensification strategies in patients with Crohn disease (CD) who have lost clinical response to the anti–tumor necrosis factor (anti-TNF) therapy infliximab.

Study Finds No Evidence of Increased Pulmonary Toxicity With Bleomycin Plus Filgrastim

February 23rd 2018

By Kelly Davio

In an animal model of bleomycin-induced lung toxicity, filgrastim increased alveolar neutrophil recruitment, pulmonary edema, and lung myeloperoxidase activity. That finding led to concerns about whether filgrastim could increase pulmonary toxicity when used together with adriamycin, bleomycin, vinblastine, and dacarbazine regimens.

Study: Corticosteroid Use May Delay Initiation of Biologics in Patients With RA

February 22nd 2018

By Kaitlynn Ely

Patients with rheumatoid arthritis (RA) who use corticosteroids can delay the initiation of biologic disease-modifying antirheumatic drugs (DMARDs), have higher incidence of adverse events (AEs), and have more healthcare costs before the initiation of biologic DMARDs than patients who do not use corticosteroids.

Could NOR-SWITCH EXTENSION Data Allay Concerns About Switching in IBD?

February 20th 2018

By Kelly Davio

Last week, at the European Crohn's and Colitis Organisation's 13th annual congress in Vienna, Austria, researchers presented data from the NOR-SWITCH EXTENSION trial—a 26-week open label extension of the NOR-SWITCH trial—concerning the inflammatory bowel disease (IBD) subgroup.

New Studies Investigate Infliximab Biosimilars in Treating CD, UC, and RA

February 20th 2018

By Samantha DiGrande

At the recent European Crohn's and Colitis Organisation’s 13th Congress in Vienna, Austria, several studies investigated the efficacy of infliximab biosimilars in treating Crohn disease (CD), ulcerative colitis (UC), and rheumatoid arthritis (RA).

Real-World Data Support Extended Treatment With Adalimumab for Noninfectious Uveitis

February 19th 2018

By The Center for Biosimilars Staff

While corticosteroids are a common treatment for uveitis, effective corticosteroid-sparing therapies are necessary to maintain disease control without risking corticosteroid-related adverse events.

4 Studies Highlight Biosimilar Switching's Effect on Patients With IBD

February 19th 2018

By Kelly Davio

At the European Crohn’s and Colitis Organisation’s 13th annual congress, held in Vienna, Austria, a number of studies explored switching from reference infliximab to its biosimilar.

PANTS Study Supports Effectiveness, Safety, and Immunogenicity of Biosimilar Infliximab

February 17th 2018

By Kelly Davio

Today, at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO), researchers released 12-month data from the Personalized Anti–Tumor Necrosis Factor (anti-TNF) Therapy in Crohn Disease (CD) Study (PANTS).